Reviews/Dry Eye Disease Treatment/Lifitegrast improves symptom scores
Lifitegrast · DED-LIFT-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Lifitegrast 5% eye drops were tested against dummy drops and against a standard lubricant in people with dry eye disease. In the largest well-controlled trial [3], people on lifitegrast reported notably less eye dryness than people on placebo, and a trial comparing it to a lubricant [2] favoured lifitegrast across several symptom questionnaires. Several real-world and single-clinic studies [4][5][6][7] pointed the same way, with symptom scores improving after treatment. The picture is not perfectly clean: one pivotal trial [1] missed the specific symptom measure it had chosen in advance, even though other symptoms improved, and much of the supporting evidence came from studies with no comparison group. The panel treated the symptom benefit as real and repeatedly seen, while staying cautious because the results were not uniform across every measure and leaned partly on uncontrolled data.
The phase III RCT OPUS-2 [3] met its co-primary symptom endpoint, with a treatment effect of 12.61 on the eye dryness visual analogue scale (P<0.0001). The active-controlled RCT [2] in 370 patients reported significantly more favourable eye dryness, ocular discomfort and OSDI scores for lifitegrast than for carboxymethylcellulose. OPUS-1 [1] missed its pre-specified co-primary subjective VR-OSDI measure (P=0.7894) but improved ocular discomfort (P=0.0273) and eye dryness (P=0.0291). Four observational studies converge in the same direction on symptom scores: OSDI improved −2.43 (P=0.011) in [4], improved versus baseline in [5] (p=0.00041), fell from 26.35 to 20.97 (P=0.03) in [7], and fewer patients reported eye dryness post-index in [6]. The contested point: The division is at the level of individual symptom instruments rather than direction: OPUS-1 [1] improved ocular discomfort and eye dryness while failing the specific VR-OSDI co-primary endpoint it had pre-specified. The two controlled RCTs [2][3] are positive on symptoms, but the remaining support [4][5][6][7] is uncontrolled and cannot by itself separate drug effect from placebo response.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
OPUS-1 [1] failed its pre-specified co-primary subjective endpoint (VR-OSDI, P=0.7894); the symptom benefit there rested on secondary/supportive measures, so 'improves symptom scores' is not uniform across every instrument.
Four of seven included studies [4][5][6][7] are uncontrolled retrospective or pre/post designs that cannot separate drug effect from placebo response, regression to the mean, or co-interventions (e.g. [7] co-administered artificial tears).
Where it remains uncertain. OPUS-1 [1] failed its pre-specified co-primary subjective endpoint (VR-OSDI, P=0.7894), and four of the supporting studies [4][5][6][7] are uncontrolled.
Aleatory
The single-centre N=14 study [5] and the 40-eye/21-patient study [7] are small enough that random variation materially affects their reported symptom changes.
Epistemic
OPUS-1 [1] missed its pre-specified co-primary subjective VR-OSDI endpoint (P=0.7894) while other symptom measures improved, leaving the benefit non-uniform across instruments.
Inferential
Pre/post designs [4][5][6][7] cannot separate drug effect from placebo response or regression to the mean, and [7] co-administered artificial tears.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows symptom benefit on some measures despite missing its specific subjective co-primary.
“The study did not meet the co-primary subjective VR-OSDI measure (P = 0.7894). However, significant improvements were observed at day 84 in ocular discomfort (P = 0.0273) and eye dryness (P = 0.0291), the most common and severe symptoms reported at baseline in both groups.”
Panel auditInternal validity: high · scope of inference: Adults with dry eye disease over 84 days of twice-daily dosing.Key limitations: co-primary subjective VR-OSDI endpoint failed (P = 0.7894) · improvement limited to selected symptoms, not the designated symptom co-primary
Active-controlled RCT positive across multiple symptom scales.
“Significantly more favorable values for EDS (except photophobia), ODS, OSDI, TFBUT, STT score, CFS score, and conjunctival redness score were achieved at week 12 with lifitegrast 5% compared to CMC 0.5%.”
Panel auditInternal validity: high · scope of inference: Adult Indian patients with DED, comparison against an artificial-tear active control rather than placebo.Key limitations: comparator is CMC 0.5% artificial tears, not placebo · photophobia did not reach significance
Controlled phase III RCT meeting a symptom co-primary endpoint — strongest evidence.
“Lifitegrast-treated subjects experienced greater improvement in eye dryness than placebo-treated subjects (treatment effect, 12.61; 95% confidence interval [CI], 8.51-16.70; P < 0.0001).”
Panel auditInternal validity: high · scope of inference: Adults with DED meeting dryness and staining entry criteria over 84 days.Key limitations: co-primary sign endpoint (inferior corneal staining) not met · more ocular TEAEs in lifitegrast arm (33.7% vs 16.4%)
3 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Controlled RCT evidence for symptom-score improvement is positive and consistent in direction, but endpoint-level inconsistency and reliance on uncontrolled studies keep it short of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent placebo-controlled replication of the symptom co-primary. Only [3] met a symptom co-primary against placebo in this corpus; [1] missed its subjective co-primary, so consistency across pivotal trials is unestablished. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An additional adequately powered placebo-controlled RCT pre-specifying a symptom co-primary endpoint and reporting it.
Open question: Does lifitegrast 5% improve symptom scores consistently across all standard symptom instruments, not only eye dryness? Why it is still open: OPUS-2 [3] met the eye dryness co-primary while OPUS-1 [1] missed its pre-specified VR-OSDI co-primary (P=0.7894).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19